CREO Share Price Performance
UK£0.10
-0.02 (-19.22%)
85.1% undervalued intrinsic discount
UK£0.70
Fair Value
Price UK£0.10
AnalystHighTarget UK£0.70
AnalystLowTarget UK£0.40
AnalystConsensusTarget UK£0.55
Fair ValueUK£0.70
Share Pricen/a
Creo Medical Group PLC Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
CREO Community Narratives
AN
Fair Value UK£0.7 85.1% undervalued intrinsic discount
Advanced Energy Platforms Will Boost Secular Demand In Healthcare
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value UK£0.4 74.0% undervalued intrinsic discount
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value UK£0.55 81.1% undervalued intrinsic discount
Minimally Invasive Interventions Will Capture New Global Markets
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
Advanced Energy Platforms Will Boost Secular Demand In Healthcare
Key Takeaways Rapid adoption of advanced products and strategic partnerships, especially in new markets like China, set up Creo for outsized growth and improved profitability beyond current expectations. Expanding clinical data, leaner operations, and strong product launches position Creo to quickly shape industry standards and achieve sustainable, self-funded profitability ahead of consensus.Read more
57
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
UK£0.7
85.1% undervalued intrinsic discount
Fair Value
Revenue
93.7% p.a.
Profit Margin
11.02%
Future PE
99.25x
Price in 2029
UK£0.89
Minimally Invasive Interventions Will Capture New Global Markets
Key Takeaways Expanding global demand and healthcare trends strongly favor Creo's advanced energy portfolio, driving sustained growth in market share, revenue, and profit margins. Strategic alliances, new product launches, and cost-saving operational changes are set to accelerate international expansion, boost utilization, and improve overall profitability.Read more
78
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
UK£0.55
81.1% undervalued intrinsic discount
Fair Value
Revenue
73.06% p.a.
Profit Margin
10.96%
Future PE
118.58x
Price in 2029
UK£0.75
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
Key Takeaways Adoption of Creo's technology faces hurdles from slow hospital procurement, budget pressures, and delayed integration of clinical evidence, restricting near-term revenue growth. Expansion is challenged by geopolitical risks, competitive medtech landscape, and potential margin pressures from ongoing high R&D spend and formidable incumbents.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£0.4
74.0% undervalued intrinsic discount
Fair Value
Profit Margin
10.73%
Future PE
126.7x
Price in 2028
UK£0.45
Trending Discussion
Recently Updated Narratives
AN
CREO: Steady Fair Value And Higher Revenue Assumptions Will Support Long Term Upside
Fair Value: UK£0.7 85.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CREO: Higher Profit Margin Assumptions Will Support Undervalued Long Term Upside
Fair Value: UK£0.55 81.1% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
Fair Value: UK£0.4 74.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Creo Medical Group PLC Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- 0.0065
- 45.65%
- 56.52%
- 6.9%
About CREO
- Founded
- 2003
- Employees
- 129
- CEO
- WebsiteView website
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
